Hyperprogression after anti-PDL-1 therapy in a patient w/ recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report [Jan 11, 2019] Mao et al. Drug Des Devel Ther https://t.co/kb7sZYxGRT #ImmunoOnc #P
Hyperprogression after anti-PDL-1 therapy in a patient w/ recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report [Jan 11, 2019] Mao et al. Drug Des Devel Ther https://t.co/kb7sZYxGRT #ImmunoOnc #P
Hyperprogression after anti-PDL-1 therapy in a patient w/ recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report [Jan 11, 2019] Mao et al. Drug Des Devel Ther https://t.co/kb7sZYg5tj #ImmunoOnc #P
Should every patient be analyzed to reduce risk of #hyperprogression? MDM2 gene amplification may result in failure of anti-PD-L1 #immunotherapy and rapid tumor growth https://t.co/DporlLBPvb #cancer
RT @mtmdphd: Hyperprogression after anti-PDL-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-…
Hyperprogression after anti-PDL-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report [Jan 11, 2019] Mao et al. Drug Des Devel Ther https://t.co/kb7sZYxGRT #ImmunoOnc
Hyperprogression after anti-PDL-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report [Jan 11, 2019] Mao et al. Drug Des Devel Ther https://t.co/kb7sZYxGRT #ImmunoOnc